CAR T-Cell Therapy with Axicabtagen Ciloleucel New Era in the Therapy of DLBCL and PMBCL

Ameri Abdol A.

首页> 外文期刊>Oncology research and treatment. >CAR T-Cell Therapy with Axicabtagen Ciloleucel New Era in the Therapy of DLBCL and PMBCL

【24h】

CAR T-Cell Therapy with Axicabtagen Ciloleucel New Era in the Therapy of DLBCL and PMBCL

机译：用Axicabtagen Ciloleucel治疗DLBCL和PMBCL治疗的汽车T细胞疗法

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology research and treatment. 》 |2019年第2期| 共2页
作者
Ameri Abdol A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. CAR T-Cell Therapy with Axicabtagen Ciloleucel New Era in the Therapy of DLBCL and PMBCL [J] . Ameri Abdol A. Oncology research and treatment. . 2019 ,第1a2期

机译：用Axicabtagen Ciloleucel治疗DLBCL和PMBCL治疗的汽车T细胞疗法
2. Yescarta (R) (Axicabtagen Ciloleucel) receives EU Marketing Authorization for the Treatment of relapsed or refractory diffuse large B-Cell Lymphoma and primary mediastinal B-Cell Lymphoma after two or more previous systemic Therapies [J] . Oncology research and treatment. . 2018 ,第10期

机译：Yescarta（r）（Axicabtagen Ciloleucel）接受欧盟营销授权，用于治疗复发或难治性弥漫性大型B细胞淋巴瘤和原发性纵隔B细胞淋巴瘤后以前的两个或更多以前的全身治疗
3. axicabtagene ciloleucel (yescarta0) in certain types of lymphoma when other treatment options have been exhausted-A CAR T-cell therapy that increases the chances of survival but frequently provokes serious adverse effects [J] . Prescrire international . 2019 ,第208期

机译：在某些类型的淋巴瘤中，当其他治疗方案已经耗尽的汽车T细胞疗法时，轴颈特异菜（Yescarta0）在疲惫不堪的T细胞疗法增加，这增加了生存的机会，但经常引起严重的不良影响
4. Chimeric-Antigen-Receptor (CAR) T-Cell Therapy, Can We Leverage the Success? [C] . Aviad Pato, Anat Globersin-Levin, Tamar Shiloach, Protein Engineering Summit. . 2018

机译：嵌合抗原受体（汽车）T细胞治疗，我们可以利用成功吗？
5. Label-Free CD8+ T-Cell Purification and Electroporation in Relation to Car T-Cell Therapy [D] . Ringwelski, Beth Anne. 2020

机译：无标记的CD8 + T细胞纯化和电穿孔与汽车T细胞疗法有关
6. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies [O] . Yun Liang, Hui Liu, Zheming Lu, 2021

机译：CD19 CAR-T表达PD-1 / CD28嵌合开关受体作为DLBCL患者用不同CD19导向的汽车T细胞疗法治疗的救助治疗
7. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies [O] . Yun Liang, Hui Liu, Zheming Lu, 2021

机译：CD19 CAR-T表达PD-1 / CD28嵌合开关受体作为DLBCL患者用不同CD19导向的汽车T细胞疗法治疗的救助治疗
8. Recurrent PET FDG Uptake after Sequential Chemotherapy and Radiation Therapy for DLBCL of the Tibia: A Case Report and Review of the Literature [R] . Miles, E. F., Balsamo, L., Turton, D. B., 2011

机译：胫骨DLBCL序贯化疗和放射治疗后复发性pET FDG摄取：病例报告及文献复习

CAR T-Cell Therapy with Axicabtagen Ciloleucel New Era in the Therapy of DLBCL and PMBCL

著录项

相似文献

相关主题

期刊订阅